Evidence map›Paper›PMID 24995318›Full record

ReviewBioMed research international2014

Second-generation antipsychotics and extrapyramidal adverse effects.

Nevena Divac, Milica Prostran, Igor Jakovcevski, Natasa Cerovac

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04807634 (Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning), which is not on this map. Cited by 135 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 7 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04807634 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning: A Randomized Controlled Trial in PoisonControl Center of Ain Shams University Hospitals

TypeinterventionalSponsorAin Shams UniversityRan2021 to 2021Enrolled30ConditionsComaArmsIntravenous Lipid Emulsion (Intralipid 20%)
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 7 syntheses or guidelines pooled it, 317 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Treatment of clozapine-associated weight gain: a systematic review.European journal of clinical pharmacology · 2015
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nevena DivacInstitute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade, Serbia.ORCID 0000-0002-5393-7521
Milica ProstranInstitute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade, Serbia.ORCID 0000-0003-3384-128X
Igor JakovcevskiUniversity Medical Center Hamburg-Eppendorf, Center for Molecular Neurobiology, Falkenried 94, 20251 Hamburg, Germany.
Natasa CerovacClinic for Neurology and Psychiatry for Children and Youth, Faculty of Medicine, University of Belgrade, Dr. Subotica 6a, 11000 Belgrade, Serbia.ORCID 0000-0003-0779-4264
University of Belgrade · RSUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antipsychotic-induced extrapyramidal adverse effects are well recognized in the context of first-generation antipsychotic drugs. However, the introduction of second-generation antipsychotics, with atypical mechanism of action, especially lower dopamine receptors affinity, was met with great expectations among clinicians regarding their potentially lower propensity to cause extrapyramidal syndrome. This review gives a brief summary of the recent literature relevant to second-generation antipsychotics and extrapyramidal syndrome. Numerous studies have examined the incidence and severity of extrapyramidal syndrome with first- and second-generation antipsychotics. The majority of these studies clearly indicate that extrapyramidal syndrome does occur with second-generation agents, though in lower rates in comparison with first generation. Risk factors are the choice of a particular second-generation agent (with clozapine carrying the lowest risk and risperidone the highest), high doses, history of previous extrapyramidal symptoms, and comorbidity. Also, in comparative studies, the choice of a first-generation comparator significantly influences the results. Extrapyramidal syndrome remains clinically important even in the era of second-generation antipsychotics. The incidence and severity of extrapyramidal syndrome differ amongst these antipsychotics, but the fact is that these drugs have not lived up to the expectation regarding their tolerability.

Indexed as

Antipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesClozapineDrug-Related Side Effects and Adverse ReactionsHumansReceptors, Dopamine D2SchizophreniaAntipsychotic AgentsBenzodiazepinesClozapineReceptors, Dopamine D2

Identifiers

PMID24995318
PMCPMC4065707
OpenAlexW2050584393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.